Cardiovascular Risk Factors and Morbidity in Long-Term Survivors of Testicular Cancer: A 20-Year Follow-Up Study

Haugnes, Hege Sagstuen; Wethal, Torgeir; Aass, Nina; Dahl, Olav; Klepp, Olbjørn; Langberg, Carl W.; Wilsgaard, Tom; Bremnes, Roy M.; Fosså, Sophie D.

doi:10.1200/jco.2010.29.9362

Cited by 356 publications

(252 citation statements)

References 37 publications

Supporting

Mentioning

232

Contrasting

Unclassified

Order By: Relevance

“…Patofizjologia jest wieloczynnikowa, obejmuje działanie prozakrzepowe i bezpośredni toksyczny wpływ na śródbłonek. Wśród chorych leczonych w przeszłości cisplatyną z powodu raka jądra obserwuje się większą zapadalność na CAD, której bezwzględne ryzyko wynosi do 8% w ciągu 20 lat [120,121].…”

Section: Cisplatynaunclassified

“…Te środki zapobiegawcze obejmują zmniejszenie dawki, stosowanie pól stycznych i osłanianie struktur serca. Do odległych powikłań leczenia raka jądra należy ponad 2-krotny wzrost ryzyka CAD ok. 10 lat po początkowym leczeniu [120]. Chorzy ci, którzy w momencie rozpoznania nowotworu są typowo w wieku 20-40 lat, często są poddani wielolekowej chemioterapii opartej na cisplatynie, w połącze-niu z radioterapią lub bez niej.…”

Section: Postępowanie Diagnostyczne I Terapeutyczneunclassified

“…U pacjentów leczonych analogami pirimidyn często obserwuje się dławicę piersiową, nieprawidłowości w EKG związane z niedokrwieniem, zaburzenia rytmu serca i zawał serca, nawet u chorych z prawidłowymi tętnicami wieńcowymi [120,287]. Ryzyko zwiększa się znacznie u pacjentów z CAD w wywiadach, a ponieważ profilaktyczne podawanie azotanów i/lub antagonistów wapnia może nie być skuteczne, należy odradzać stosowanie analogów pirimidyn u tych osób [288][289][290].…”

Section: Analogi Pirimidynunclassified

See 2 more Smart Citations

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

Zamorano¹,

Lancellotti²,

Muñoz³

et al. 2016

Kardiol Pol

View full text Add to dashboard Cite

Section: Cisplatynaunclassified

Section: Postępowanie Diagnostyczne I Terapeutyczneunclassified

Section: Analogi Pirimidynunclassified

See 1 more Smart Citation

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

Zamorano¹,

Lancellotti²,

Muñoz³

et al. 2016

Kardiol Pol

View full text Add to dashboard Cite

“…8 CVD emerges a few years post-treatment and the incidence is cumulative over subsequent years. 9,10 In parallel to CVD, metabolic disturbances -including obesity and central fat distribution indicated by large waist circumference, hypertension, dyslipidaemia and diabetes -which may be aggravated by cancer therapies, all also develop progressively post-treatment.…”

Section: Monitoring Risk Factors Of Cardiovascular Disease In Cancer mentioning

confidence: 99%

Monitoring risk factors of cardiovascular disease in cancer survivors

et al. 2017

View full text Add to dashboard Cite

There exist published literature for cardiovascular disease (CVD) risk monitoring in cancer survivors but the extent of monitoring in clinical oncology practice is unknown. We performed an interactive survey at a Royal College of Physicians conference (11 November 2016) attended by practitioners with an interest in late effects of cancer treatment and supplemented the survey with an audit among 32 lung cancer survivors treated at St Peter's NHS Hospital in 2012-2016. Among the practitioners, 40% reported CVD risk monitoring performed at least annually, which is compatible with European Group for Blood and Marrow Transplantation Guidelines, but 31% indicated that monitoring was never performed. In contrast, 77% felt that at least an annual assessment was required (p<0.001). Corroborating these data, among the lung cancer survivors, 31% and 16% had lipids or glucose/HbA1C measured annually, and 28% and 31% had never had these tests performed since their cancer treatment. Alerting healthcare providers to review protocols may help reduce CVD after cancer treatments.

show abstract

“…6 They are divided into nine categories according to their pathophysiology and clinical manifestation: myocardial dysfunction and heart failure; coronary artery disease; valvular disease; arrhythmias, especially those induced by QT-prolonging drugs; arterial hypertension; thromboembolic disease; peripheral vascular disease and stroke; pulmonary hypertension; and pericardial complications. 9 Detection of CV complications from the cancer treatment requires the use of a broad spectrum of diagnostic techniques, such as ECG, blood pressure monitoring, CV imaging methods, biomarker testing, coronary arteriography, cardiac catheterization, etc. Therefore, there is a need for collaboration from a broad spectrum of specialists covering not only oncology, but all fields of cardiology.…”

Section: Wide Spectrum Of Cardiovascular Complications Of Cancer Treamentioning

confidence: 99%

The Future Role of Cardio-oncologists

Pudil

2017

Cardiac Failure Review

View full text Add to dashboard Cite

Access at: www.CFRjournal.com Cardiovascular (CV) disease and cancer remain the two most common causes of mortality in developed countries. According to recent data from the American Cancer Society, the lifetime probability of being diagnosed with an invasive cancer is higher for men (43 %) than for women (38 %). 1Within the last few decades the progress in the treatment of malignant diseases significantly improved survival of oncological patients. The decreased mortality is driven by both improved diagnostic and therapeutic modalities; however, the improved survival of oncological patients can be limited by adverse effects associated with intensive antitumorous treatment. In particular, cardiotoxicity may compromise the effectiveness of the anticancer therapy, independently of the oncological prognosis, and can negatively affect survival and quality of life of oncological patients.This includes the development of newly diagnosed CV problems, or the exacerbation of previously identified CV disease. Rates of CV problems from cancer-related therapeutics have been reported to be in excess of 30 %, and cardiotoxicity is the second most common cause of morbidity and mortality in cancer survivors.2,3 The number of patients at risk of problems are high. According to the latest data, on 1 January 2016 more than 15.5 million Americans with a history of cancer were alive, and this number is projected to reach more than 20 million by 1 January 2026.Furthermore, 56 % of survivors were diagnosed within the past 10 years, and almost half (47 %) were aged 70 years or older. 4 Similarly, there is an increasing number of patients with malignancy who have a history of CV disease or an increased CV risk. Therefore, the CV problems in oncological patients are not only medical but also social and economic problems, and new strategies to solve this topic are needed. 5 This brief review focuses on some issues that need to be addressed in the near future. Wide Spectrum of Cardiovascular Complications of Cancer TreatmentThe first clinical manifestation of adverse effects from anticancer drugs on the CV system was depression of the left ventricle function leading to heart failure in patients treated with anthracyclines. Therefore, the term there is a need for collaboration from a broad spectrum of specialists covering not only oncology, but all fields of cardiology. Basic Concept for the Management of Patients Treated with Potentially Cardiotoxic DrugsIt has been shown that early detection and adequate treatment of CV complications can improve survival and the quality of life of oncological Abstract Cardiovascular (CV) disease and cancer remain the two most common causes of mortality in developed countries; however, progress in the treatment of malignant diseases significantly improved survival of oncological patients. Similarly, there is an increased number of the patients with malignancy who have a history of CV disease or an increased CV risk. Rates of CV problems from cancer-related therapeutics are high, and cardiotoxicity is the se...

show abstract

Cardiovascular Risk Factors and Morbidity in Long-Term Survivors of Testicular Cancer: A 20-Year Follow-Up Study

Abstract: Treatment with infradiaphragmatic RT and/or cisplatin-based chemotherapy, particularly the BEP regimen, increases the long-term risk for CVD in survivors of TC.

Cited by 356 publications

References 37 publications

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

Monitoring risk factors of cardiovascular disease in cancer survivors

The Future Role of Cardio-oncologists

Contact Info

Product

Resources

About